Skip Navigation LinksHome > July 2007 - Volume 2 - Issue 7 > The IASLC Lung Cancer Staging Project: Proposals for the Rev...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0b013e31807a2f81
IASLC Staging Article

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

Rami-Porta, Ramón MD*; Ball, David MD, FRANZCR†; Crowley, John PhD‡; Giroux, Dorothy J. MS‡; Jett, James MD§; Travis, William D. MD‖; Tsuboi, Masahiro MD¶; Vallières, Eric MD#; Goldstraw, Peter MB, FRCS**; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions

Free Access
Article Outline
Collapse Box

Author Information

From the *Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain; †Peter MacCallum Cancer Centre, Melbourne, Australia; ‡Cancer Research and Biostatistics, Seattle, Washington; §Mayo Clinic, Rochester, Minnesota; ‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶Tokyo Medical University, Tokyo, Japan; #Swedish Cancer Institute, Seattle, Washington; and **Royal Brompton Hospital, London, United Kingdom.

a,b,c,dSee Appendix 1.

Eli Lilly and Company provided funding to support the International Association for the Study of Lung Cancer (IASLC) Staging Committee’s work to establish a database and to suggest revisions to the sixth edition of the TNM classification for lung cancer (staging) through a restricted grant. Lilly had no input into the committee’s analysis of the data or into their suggestions for revisions to the staging system. Dr. Jett has served on a Data Safety Monitoring Board for Phase III clinical trials for Pfizer and Astra Zeneca and on an advisory panel for Lilly, Inc. None of those drugs are discussed or mentioned in this manuscript.

Address for correspondence: Ramón Rami-Porta, MD, Thoracic Surgery Service, Hospital Mutua de Terrassa, Plaza Dr. Robert 5, 08221 Terrassa (Barcelona), Spain. E-mail: rramip@terra.es

Collapse Box

Abstract

Purpose: To propose changes in the seventh revision of the tumor, node, metastasis (TNM) classification for lung cancer.

Methods: Data on 100,869 patients were submitted to the international database, and data for 18,198 of these patients fulfilled the inclusion criteria for the T component analysis. Survival was calculated for clinical and pathologic T1, T2, T3, T4NOMO completely resected (R0), and for each T descriptor. A running log-rank test was used to assess cutpoints by tumor size. Results were internally and externally validated.

Results: On the basis of the optimal cutpoints, pT1NOR0 was divided into pT1a ≤2 cm (n = 1816) and pT1b >2 to 3 cm (n = 1653) with 5-year survival rates of 77 and 71% (p < 0.0001). The pT2NOR0 cutpoints resulted in pT2a >3 to 5 cm (n = 2822), pT2b >5 to 7 cm (n = 825), and pT2c >7 cm (n = 364). Their 5-year survival rates were 58, 49, and 35% (p < 0.0001). For clinically staged N0, 5-year survival was 53% for cT1a, 47% for cT1b, 43% for cT2a, 36% for cT2b, and 26% for cT2c. pT3NO (n = 711) and pT4 (any N) (n = 340) had 5-year survival rates of 38 and 22%. pT4 (additional nodule(s) in the same lobe) (n = 363) had a 5-year survival rate of 28%, similar to pT3 (p = 0.28) and better than other pT4 (p = 0.0029). For pM1 (ipsilateral pulmonary nodules) (n = 180), 5-year survival was 22%, similar to pT4. For cT4-malignant pleural effusion/nodules, 5-year survival was 2%.

Conclusion: Recommended changes in the T classification are to subclassify T1 into T1a and T1b, and T2 into T2a and T2b; and to reclassify T2c and additional nodule(s) in the same lobe as T3, nodule(s) in the ipsilateral nonprimary lobe as T4, and malignant pleural or pericardial effusions as M1.

The sixth edition of the Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) has served as the current tumor, node, metastasis (TNM) staging system for lung cancer since 2002. A new staging project was initiated by the International Association for the Study of Lung Cancer (IASLC) in 1999, with the goal of providing data for the next revision of the international staging system.1,2 The Cancer Research and Biostatistics office (CRAB) in Seattle, Washington, was selected to develop the database by collecting cases from around the world and to perform statistical analysis of TNM factors in the new dataset. Investigators were invited to share information from their local databases with CRAB. Data on a total of 100,869 patients treated for primary lung cancer from 1990 to 2000 were submitted to CRAB.3 Subcommittees were formed from the parent IASLC International Staging Committee, to analyze the new international dataset and to propose appropriate changes for the next revision of the TNM classification for lung cancer. This manuscript provides an analysis of the T descriptors and recommends changes for the next revision of the UICC and AJCC staging system.

Back to Top | Article Outline

MATERIALS AND METHODS

Objectives

To study the prognostic impact of the different descriptors that define the T component of the TNM classification in patients with N0M0 tumors, and to see whether they are useful in classifying non-small cell lung cancer (NSCLC), the T descriptors subcommittee established the following issues as priorities:

* Clinical and pathologic tumor size in T1 and T2 tumors, excluding other T2 descriptors.

* Clinical and pathologic T2 descriptors, in general and stratified by tumor size: atelectasis/pneumonitis of less than the whole lung, visceral pleural involvement, and endobronchial location.

* Clinical and pathologic T3 descriptors: atelectasis/pneumonitis of the whole lung, parietal pleura invasion, chest wall invasion, diaphragmatic invasion, parietal pericardial invasion, mediastinal pleural invasion, endobronchial location, invasion of the phrenic nerve, and Pancoast tumor.

* Clinical and pathologic T4 descriptors: carinal invasion, invasion of mediastinal tissue, invasion of the great vessels, invasion of the heart, invasion of the recurrent laryngeal nerve, invasion of the esophagus, invasion of the trachea, invasion of the vertebral body, additional nodules in the same lobe as the primary tumor, and malignant pleural and pericardial effusion.

* Stratification of results by cell type.

* Stratification of results by completeness of resection.

Back to Top | Article Outline
Population

The total number of patients submitted to CRAB was 100,869,3 of whom 18,018 patients met the T descriptors subcommittee’s initial analytic requirements of M0 NSCLC, a complete set of either cTNM or pTNM, and sufficient T descriptor details to support the assigned T stage (Table 1). On the basis of recommendations by the M descriptors subcommittee, 180 patients with tumors staged as M1 because of additional nodules in an ipsilateral different lobe from the primary tumor were added to the T component analysis, bringing the total analyzed to 18,198. These 18,198 patients originated from four geographical areas, including Europe, North America, Asia, and Australia, and from a variety of data sources (see Table 2).

Table 1
Table 1
Image Tools
Table 2
Table 2
Image Tools

The NSCLC M0 population with complete cTN included 38,162 patients (Table 1). There was sufficient clinical T descriptor information for 5760 patients, including 339 treated preoperatively, distributed as follows: 68% cN0, 5% cN1, 21% cN2, 4% cN3, and 3% cT4Nx. As for the analysis of the pathologic T, the population excluded neoadjuvant treatment and consisted of 26,177 M0 patients with complete pTN (substitutions of cM for pM were permitted). In 15,234 of these patients, the tumors had sufficient pT descriptors and were distributed as follows: 64% pN0, 19% pN1, 17% pN2, 0.5% pN3, and 0.3% pT4Nx. Table 3 summarizes the distribution of histologic types according to clinical and pathologic T factors. Complete resection (R0) was achieved in 85% of tumors with any pN, and this rate increased to 89% in those with no nodal involvement (pN0) (Table 4).

Table 3
Table 3
Image Tools
Table 4
Table 4
Image Tools
Back to Top | Article Outline
Validation Analysis

The approach to validation was suggested by the validation and methodology subcommittee and is described in more detail elsewhere.4 The validation analysis was performed in the general population and in the population of patients with no nodal disease. Complete and incomplete resections were included in the population for analysis of pathologic T.

Back to Top | Article Outline
Internal Validation

The internal validation approach was to compare results of interest among two descriptors, each divided into three strata: types of databases (consortium/surgical series versus clinical trials versus series/registries), and geographic regions (North America versus Asia/Australia versus Europe). If the direction and magnitude of effects were relatively consistent within these subgroups, the results were considered validated.

The population for internal validation of clinical T included 5760 patients. For the validation of pathologic T, the population consisted of 15,234 patients. Table 2 shows the origins of these patients and their data sources in detail.

Additionally, in the analysis of tumor size, the sample pT1- and pT2 N0 R0 cases with size measurements by pathologic findings were divided into a learning set of approximately two thirds (n = 4891) and a validation set of the remaining third (n = 2589). The learning set was used to develop an optimal cutpoint for tumor size, which was confirmed in the validation set. Cases were selected for the learning versus validation sets at random after balancing on attributes of size, T status, N status, region, and type of database.

Back to Top | Article Outline
External Validation

For external validation of the T component analysis, cases of NSCLC diagnosed from 1990 to the end of 2000 were chosen from the Surveillance, Epidemiology and End Results (SEER) registry database.

Back to Top | Article Outline
Statistical Analysis

Survival was measured from the date of entry (date of diagnosis for registries, date of registration for protocols) for clinically staged data and from the date of surgery for pathologically staged data; it was calculated by the Kaplan-Meier method. Prognostic groups were assessed by Cox regression analysis, using the SAS System for Windows version 9.0 PHREG procedure.

In the derivation of tumor size cutpoints, the running log-rank statistic produced by each hypothetical cutpoint in the pN0 R0 learning set was graphed against tumor size, and the tumor size that coincided with the highest log-rank statistic was chosen as the optimal cutpoint, after rounding to the nearest whole centimeter.5 The chosen cutpoint was then tested in the pN0 R0 validation set and explored in incompletely resected cases and in all the other nodal stage groups, and also in clinically obtained measurements of tumor size. S-Plus version 7.0 was the software used to generate the log-rank statistics.

Back to Top | Article Outline

RESULTS

Tumor Size Cutpoints in Clinical and Pathologic T1 and T2

When comparing overall survival between groups of patients defined by tumor size, we found that survival differences were optimized at size cutpoints of 2, 3, 5, and 7 cm. These tumor size cutpoints were chosen on the basis of pathologic measurements from completely resected cases in the learning set and were then tested in the remaining pathologic and clinical data. In the learning set of 2284 R0 patients with pT1 N0 tumors (two thirds of all such patients), the highest log-rank statistic coincided with a pathologic tumor measurement of 2.0 cm (Figure 1). For the learning set for 2607 R0 patients with pT2 N0 tumors, the highest log-rank statistic occurred at a pathologic tumor measurement of 7.3 cm, with the second-highest split at 5.0 cm (Figure 2). These four tumor size cutpoints were confirmed in the validation set of 2589 pT1- and pT2 N0 R0 cases with p values of 0.0017, <0.0001, <0.0001, and 0.0125 for each comparison between the resulting five adjacent tumor size groups, starting with the smallest tumors. In both the learning set and the validation set, tumor sizes were distributed as follows: 23% smaller than or equal to 2 cm; 23% larger than 2 cm but smaller than 3 cm; 37% larger than 3 cm but smaller than 5 cm; 11% larger than 5 cm but smaller than 7 cm; and 5% larger than 7 cm. Figure 3.

Figure 1
Figure 1
Image Tools
Figure 2
Figure 2
Image Tools
Figure 3
Figure 3
Image Tools

In all pathologically staged N0 R0 cases (learning and validation sets combined), for patients with tumors no larger than 2 cm (n = 1816), median survival was not reached. For those larger than 2 cm but smaller than 3 cm (n = 1653), survival was 113 months. For those with tumors larger than 3 cm but smaller than 5 cm (n = 2822), survival dropped to 81 months. For those with tumors larger than 5 cm but smaller than 7 cm (n = 825), survival was 56 months. For those with tumors larger than 7 cm (n =364), survival was 29 months. See Figures 1, 2, and 3 and Table 5 and 6 for details; the tables also summarize results for N0 cases irrespective of completeness of resection, and for any N status.

Table 5
Table 5
Image Tools
Table 6
Table 6
Image Tools

When clinically staged N0 cases were grouped into the five size categories as above, median survival was not significantly different between the smallest two size groups (68 vs 52 months, p = 0.09); nevertheless, comparisons between adjacent groups yielded significant survival differences at the 3-cm cutpoint (43 vs 30 months, p = 0.001) and at the 5-cm cutpoint (30 vs 17 months, p = 0.008). Survival for patients with tumors larger than 7 cm was not significantly different from cT3 tumors (17 versus 19 months, p = 0.61) (Table 6, Figure 4).

Figure 4
Figure 4
Image Tools

Subgroup analyses of these tumor size cutpoints within different histologic types of NSCLC yielded similar results. The differences between size categories diminished as nodal disease advanced.

Back to Top | Article Outline
Pathologic T3, T4, and M1 by Ipsilateral Pulmonary Nodules

In our analyses of overall survival among pathologically staged cases categorized by UICC sixth edition as T3, T4, and M1 by additional nodule (same side, different lobe), the following prognostic groups emerged: T3 (n = 1224), with median survival of 24 months; T4 exclusively by same-side nodules (n = 363), with survival of 21 months; T4 by pleural dissemination, including malignant pleural effusion or pleural nodules (n = 245), with survival of 18 months; other T4 (n = 340), with survival of 15 months; and M1 by same side/different lobe (n = 180), with survival of 18 months. In contrast to the analysis of tumor size, the primary comparisons of survival described below and shown in Figure 5 for these later-stage cases include all pathologically staged cases, irrespective of completeness of resection or nodal status. Comparisons are summarized in Table 7 for various populations (N0 R0; any R N0; and any R, any N).

Figure 5
Figure 5
Image Tools
Table 7
Table 7
Image Tools
Back to Top | Article Outline
Pathologic T4 by Ipsilateral Pulmonary Nodules

Among patients with T4 tumors by additional nodules in the same lobe, 210 (58%) were adenocarcinomas, 109 (30%) were squamous cell carcinomas, and the remaining 44 (12%) were adenosquamous, bronchioloalveolar, or unspecified NSCLC. These patients were observed to have survival similar to T3 patients (p = 0.2838). They had markedly better survival than patients staged T4 for “other” reasons (p = 0.0029)—that is, invasion of mediastinal structures and excluding pleural dissemination.

Back to Top | Article Outline
Pathologic M1 by Ipsilateral Pulmonary Nodules in a Different Lobe from the Primary Tumor

Survival for the 180 patients whose tumors were staged M1 by ipsilateral separate-lobe pulmonary nodules was similar to the comparator T4 group (p = 0.41), with 5-year survival rates of 22% for both groups. Their histological types were adenocarcinoma in 129 (72%) and squamous cell carcinoma in 27 (15%); the remaining 24 (13%) were adenosquamous, bronchioloalveolar carcinoma, or unspecified NSCLC.

Back to Top | Article Outline
Clinical T4

In practice, the discovery of same-side and, especially, same-lobe nodules is primarily a surgical rather than a clinical finding; thus, there were few patients with tumors staged cT4 (n = 17) or cM1 (n = 24) on the basis of same-side pulmonary nodules. For this reason, comparisons involving same-side nodules were not explored in detail in the clinically staged data. Conversely, malignant pleural effusions are more commonly diagnosed clinically and preclude surgery as an option. Five-year and median survival rates for the 471 patients with pleural dissemination were 2% and 8 months versus 14% and 13 months for the 418 in the comparator cT4 group (excluding same-side nodules), and survival between these two groups was statistically significantly different (p < 0.0001) (Table 8, Figure 6).

Table 8
Table 8
Image Tools
Figure 6
Figure 6
Image Tools
Back to Top | Article Outline
Other T Descriptors

Other T2 descriptors (visceral pleural invasion and partial atelectasis), and the different T3- and T4 descriptors (except for the additional pulmonary nodule(s) in the lobe of the primary tumor) could not be evaluated, either because of the small number of patients, the inconsistent clinical and pathologic results, or lack of validation.

Back to Top | Article Outline
Validation of Results

Complete details of the internal and external validations of these findings are published elsewhere.4 In summary, the subclassification of T1 and T2 into T1a and T1b, and T2a and T2b, respectively, driven by Asian data for pathologic size and by European data for clinical size, showed distinct differences in survival for both clinical and pathologic subgroups. These findings were consistent in most databases and in the SEER external validation, both in the overall population and in the surgical subset.

The finding that T2 tumors larger than 7 cm were more like T3 than other T2 was observed to be both internally and externally valid. The population-based SEER data indicated more of a risk continuum by size than was seen in the project dataset, but the >7-cm group’s prognosis was closer to the T3 group than it was to the rest of the T2 group.

The influence of histologic type on the prognostic impact of tumor size was also evaluated, and the cutpoints of 2, 3, 5, and 7 cm were valid within all major cell types.

Cases with additional nodules in the primary lobe consistently experienced better survival than other T4 cases. Nevertheless, we were not able to look at this issue using cTNM, because this T descriptor was generally only documented in the surgical data. When restricted to those treated with surgery in the SEER data, the additional nodule group’s survival was better than those even with T3 disease.

The finding that additional nodules in a different lobe of the ipsilateral lung had better prognosis than the present classification (M1) would indicate (and similar to that of T4) was driven by consortia/surgical series pathologic data that were almost all from the Asia/Australia region. This finding was also supported by the European pathologic data and the SEER registry.

Data supporting the reclassification of pleural dissemination from T4 to M1 were driven by the European and North American series in the clinically staged analyses and by pathologic series from consortium/surgical series. These findings also were supported by the SEER data.

Back to Top | Article Outline

DISCUSSION

Lung cancer is responsible for more cancer deaths than any other cancer worldwide, both in men and women. Complete resection gives the highest probability of long-term remission and even cure, but only about 25% of patients are candidates for surgical treatment at the time of diagnosis. Poor performance status, comorbidity, and either locally advanced or metastatic disease exclude the rest from surgical intervention. Lung cancer classification and staging assess the anatomical extension of the tumor; this is critical to choosing a therapy and provides information on prognosis. The latest (i.e., the sixth) edition of the TNM classification of lung cancer6,7 was based on 5319 patients treated for primary lung cancer at The University of Texas–MD Anderson Cancer Center (4351 patients) from 1975 to 1988 or by the National Cancer Institute Cooperative Lung Cancer Study Group (968 patients) from 1977 to 1982.8 Thus, the international system for staging lung cancer is based on a national database of patients who were treated mainly in one institution. Realizing that this database was becoming relatively old and that new technology was being applied to lung cancer staging, the IASLC established an international staging committee with the purpose of collecting a large international database of patients treated for primary lung cancer, to formulate, with the agreement of the UICC and the AJCC, a new revision of the TNM classification of lung cancer, to be published in 2009. More than 100,000 patients were submitted to CRAB, the data-managing center, and more than 81,000 met all inclusion criteria.3 These patients had been treated from 1990 to 2000. This period was chosen because no major changes had been introduced in clinical practice regarding lung cancer staging, and computed tomography scans had been widely used all over the world to stage lung cancer.

The analyses conducted on the population of patients with information on the T descriptors revealed several findings that could be used to refine the present definitions of the T component of the TNM classification. In addition to the two size criteria, that were based on the 3-cm landmark, three more cutpoints were identified, and the five resulting size groups showed distinct survival differences. The results show that T1 tumors can be divided into two subgroups on the basis of the best cutpoints identified by the running log-rank analysis. Therefore, without altering the 3-cm landmark between T1 and T2 tumors, T1 tumors can be subdivided into two prognostic groups: those 2 cm or smaller (T1a) and those larger than 2 cm but no larger than 3 cm (T1b). This finding was validated by geographical region and database type, and by the SEER registry data. Results from other series support this division. Padilla et al.,9 in a study on 158 patients with pT1- or pT2 NSCLC 3 cm or smaller in diameter, found that those 2 cm or smaller had better survival, and that size was a better indicator of prognosis than endobronchial invasion and visceral pleura involvement. Mulligan et al.10 also found that tumors 2 cm or smaller in diameter had a different prognosis from that of larger tumors; they have suggested that these tumors alone should constitute T1, and that those larger than 2 cm but no larger than 4 cm, or T1 with pleural invasion, should constitute T2. In a large Japanese multicenter series of patients with T1 NSCLC, the same subgroups as those found in the analysis of the IASLC database were formed according to tumor size. Five-year survival rates for those clinically staged as T1a (1204 patients) and T1b (993 patients) were 77.5 and 69.3%, respectively (p < 0.001). For those pathologically staged as T1a (1065 patients) and T1b (886 patients), 5-year survival rates were 83.7 and 76%, respectively (p < 0.001).11

This study also shows that T2 tumors can be divided into three subgroups of different prognosis; these could be called T2a (larger than 3 cm but no larger than 5 cm), T2b (larger than 5 cm but no larger than 7 cm), and T2c (larger than 7 cm). These cutpoints were consistent across databases and geographical regions and were supported by the SEER external validation. Other authors, on the basis of results from institutional series, have reported on the prognostic significance of the 5-cm landmark and have suggested that T2 tumors larger than 5 cm should be upgraded.12,13 A multicenter study on clinical and pathologic size found that the prognostic landmarks were 2, 4, and 7 cm, and suggested that T2 tumors larger than 7 cm should be upgraded to T3.14,15 This is in agreement with the findings of this study: T2 tumors larger than 7 cm and T3 tumors have similar prognosis. This finding has been validated in all geographic areas and databases of the IASLC for clinical or pathologic size and in the SEER registry for both.

The results of this study also have shown that T4 tumors classified by the presence of additional nodules in the lobe of the primary tumor have better prognosis than other T4 tumors and similar prognosis to T3 tumors. This finding has been validated by the SEER registry and by all geographic areas and databases with sufficient numbers of patients. This is a very controversial point in the TNM classification, and large and small series have contradictory results. In a series of 1534 patients with completely resected NSCLC, the 5-year survival rate for 54 patients with T4 tumors without additional nodules was similar to that of 105 patients with T4 tumors by additional nodules: 34% in both cases.16 Nevertheless, it has been reported from smaller series that survival of patients with T4 tumors by additional nodules can be better than that of those with stage IIIB tumors17 or similar to that of patients with stage IV tumors.18 These discrepancies may be attributable to the few patients with T4 tumors by additional nodules or to the difficulty in determining whether an additional nodule of the same histological type as the primary tumor is a second primary or a metastasis. Their different biologic behaviors may be responsible for the prognostic differences found in the quoted series.

Tumors associated with malignant pleural effusion are now classified as T4 for mere taxonomic reasons: all situations within the hemithorax of the primary tumor should belong to the T component, except for nodules in another ipsilateral lobe. Nevertheless, their prognosis is much worse than that of other T4 tumors; this will be shown in a forthcoming article in the context of M1 disease. Further, they are usually treated in the same manner as patients with M1 disease. In the present study, the 5-year survival rate for patients with clinical malignant pleural effusion was 2%, and the 5-year survival rate for patients with other cT4 tumors was around 30%. Survival was better for patients with pathologic malignant pleural effusion, with 5-year survival rates of around 20%, but there were few patients in this situation, and the extent of their disease must have been very reduced and amenable to complete resection, which is not the rule with malignant pleural effusion. The poor prognosis of this situation was validated in Europe and North America and in the clinical and pathologic series of the SEER registry.

The main limitation of this study is that most databases that have contributed to the IASLC international database were not designed to study the TNM classification. So, although more than 81,000 patients fulfilled the inclusion criteria, not all their records included information on the T descriptors that defined a certain T. Table 1 shows a summary of the number of patients with cT and pT tumors. For example, the population of surgical patients with cN0 tumors was 15,347, but only 3554 (23%) had sufficient information on T descriptors. This drop in patient numbers increased with higher T factors, and it is only 19% (110 of 582) in patients with cT4 tumors. This loss of information is even more evident in patients who did not undergo surgical treatment (Table 1). Lack of T descriptors is the reason most T2- and T3 descriptors, and all T4 descriptors (except for the additional nodule(s) in the same lobe as the primary tumor), could not be validated with the analysis of the IASLC international database. This limitation could be overcome with a prospective database with the objective of studying the TNM classification. In this database, the specific T descriptors for each tumor should be registered.

From the analysis of the T component of the TNM classification in the IASLC international database, we can conclude that there is sufficient validated information to consider the following recommendations for changes in the seventh edition of the TNM classification of lung cancer: 1) to subclassify T1 as T1a (≤2 cm) or T1b (>2 cm to ≤3 cm); 2) to subclassify T2 as T2a (>3 cm to ≤5 cm or T2 by other factor and ≤5 cm) or T2b (>5 cm to ≤7 cm); 3) to reclassify T2 tumors >7 cm as T3; 4) to reclassify T4 tumors by additional nodule(s) in the lung (primary lobe) as T3; 5) to reclassify M1 by additional nodule(s) in the ipsilateral lung (different lobe) as T4; and 6) to reclassify pleural dissemination (malignant pleural or pericardial effusions, pleural nodules) as M1.

The recommendations drawn from this study are solidly based. The database used is the largest ever collected for the purpose of evaluating lung cancer classification and staging. Data were collected from worldwide sources representing four distinct geographical areas. Information was collected both from highly audited datasets, such as clinical trials, and from registries, which generally are less strictly audited. Finally, the findings of this study hold when comparing different geographic regions, histologic types, and data sources, thus making the findings generalizable.

This is one of several papers from the IASLC International Staging Committee that has the purpose of presenting our current considerations on the basis of analysis of the large dataset submitted for this project. With this publication, we hope to generate feedback from the community of physicians working in the lung cancer field to engage any positive suggestions that might allow for improvements in the present TNM classification of lung cancer.

Back to Top | Article Outline

REFERENCES

1. Goldstraw P. Report on the international workshop on intrathoracic staging, London, October 1996. Lung Cancer 1997;18:107–111.

2. Goldstraw P. The International Staging Committee of the IASLC: its origins and purpose. Lung Cancer 2002;37:345–348.

3. Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol 2006;1:281–286.

4. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forthcoming (7th) edition of the TNM classification for lung cancer. J Thorac Oncol. In press.

5. Crowley J, LeBlanc M, Jacobson J, Salmon S. Some exploratory tools for survival analysis. In Lecture Notes on Statistics. Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. New York: Springer, 1997:199–229.

6. Sobin LH, Wittekind C (Eds.), International Union Against Cancer (UICC) TNM Classification of Malignant Tumours, 6th Ed. New York: Wiley-Liss, 2002:99–103.

7. Greene FL, Page DL, Fleming ID, et al (Eds)., American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, 6th Ed. New York: Springer, 2002:191–203.

8. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–1717.

9. Padilla J, Calvo V, Peñalver JC, Sales G, Morcillo A. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997;63:324–326.

10. Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Lung cancer staging: a case for a new T definition. Ann Thorac Surg 2006;82:220–226.

11. Asamura H, Goya T, Koshiishi Y, et al. How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations. J Thorac Cardiovasc Surg 2006;132:316–319.

12. Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimetres in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:907–912.

13. Takeda S, Fukai S, Komatsu H, et al. Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer. Ann Thorac Surg 2005;79:1142–1146.

14. Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Clinical tumour size and prognosis in lung cancer. Eur Respir J 1999;14:812–816.

15. López-Encuentra A, Duque-Medina JL, Rami-Porta R, Gómez de la Cámara A, Ferrando P; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery. Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicentre study of 1,020 patients. Chest 2002;121:1515–1520.

16. Okumura T, Asamura H, Suzuki K, Kondo H, Tsuchiya R. Intrapulmonary metastasis of non-small cell lung cancer: a prognostic assessment. J Thorac Cardiovasc Surg 2001;122:24–28.

17. Miyazawa M, Shiina T, Kurai M, et al. Assessment of the new TNM classification for resected lung cancer. Kyobu Geka 2000;53:915–918.

18. Hosokawa Y, Matsuge S, Murakami Y, et al. Validity and controversies in the new postoperative pathologic TNM classification based on the results of surgical treatment of non-small cell lung cancer. Kyobu Geka 2000;53:910–914.

Back to Top | Article Outline
APPENDIX 1.
aIASLC International Staging Committee

P. Goldstraw (chairperson), Royal Brompton Hospital, London, United Kingdom; D. Ball, Peter MacCallum Cancer Centre, Melbourne, Australia; E. Brambilla, Laboratoire de Pathologie Cellulaire, Grenoble Cedex, France; P.A. Bunn, University of Colorado Health Sciences, Denver, CO, USA; D. Carney, Mater Misericordiae Hospital, Dublin, Ireland; T. Le Chevalier, Institute Gustave Roussy, Villejuif, France; J. Crowley, Cancer Research and Biostatistics, Seattle, WA, USA; R. Ginsberg (deceased), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; P. Groome, Queen’s Cancer Research Institute, Kingston, Ontario, Canada; H.H. Hansen (retired), National University Hospital, Copenhagen, Denmark; P. Van Houtte, Institute Jules Bordet, Brussels, Belgium; J-G. Im, Seoul National University Hospital, Seoul, South Korea; J.R. Jett, Mayo Clinic, Rochester, MN, USA; H. Kato (retired), Tokyo Medical University, Tokyo, Japan; T. Naruke (deceased), Saiseikai Central Hospital, Tokyo, Japan; E.F. Patz, Duke University Medical Center, Durham, NC, USA; P.E. Postmus, Free University Hospital, Amsterdam, The Netherlands; R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, Spain; V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; J.P. Sculier, Institute Jules Bordet, Brussels, Belgium; F.A. Shepherd, University of Toronto, Toronto, Ontario, Canada; Y. Shimosato (retired), Tokyo Medical College, Tokyo, Japan; L. Sobin, Armed Forces Institute of Pathology, Washington, DC, USA; W. Travis, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; M. Tsuboi, Tokyo Medical University, Tokyo, Japan; R. Tsuchiya, National Cancer Centre, Tokyo, Japan; E. Vallières, Swedish Cancer Institute, Seattle, WA, USA; Yoh Watanabe (deceased), Kanazawa Medical University, Uchinada, Japan; H. Yokomise, Kagawa University, Kagawa, Japan; and Z. Shaikh (research assistant), Royal Brompton Hospital, London, United Kingdom.

Back to Top | Article Outline
bCancer Research and Biostatistics

J.J. Crowley, K. Chansky, D. Giroux, and V. Bolejack, Seattle, WA, USA.

Back to Top | Article Outline
cObservers to the Committee

C. Kennedy, University of Sydney, Sydney, Australia; M. Krasnik, Gentofte Hospital, Copenhagen, Denmark; J.P. van Meerbeeck, University Hospital, Ghent, Belgium; J. Vansteenkiste, Leuven Lung Cancer Group, Leuven, Belgium.

Back to Top | Article Outline
dParticipating Institutions

O. Visser, Amsterdam Cancer Registry, Amsterdam, The Netherlands; R. Tsuchiya, T. Naruke (deceased), National Data from Japan; J.P. Van Meerbeeck, Flemish Lung Cancer Registry–VRGT, Brussels, Belgium; H. Bülzebruck, Thoraxklinik am Universitatsklinikum, Heidelberg, Germany; R. Allison and L. Tripcony, Queensland Radium Institute, Queensland, Australia; X. Wang, D. Watson, and J. Herndon, Cancer and Leukemia Group B (CALGB), USA; R.J. Stevens, Medical Research Council Clinical Trials Unit, London, United Kingdom; A. Depierre, E. Quoix, and Q. Tran, Intergroupe Francophone de Cancerologie Thoracique (IFCT), France; J.R. Jett and S. Mandrekar, North Central Cancer Treatment Group (NCCTG), USA; J.H. Schiller and R.J. Gray, Eastern Cooperative Oncology Group (ECOG), USA; J.L. Duque-Medina and A. Lopez-Encuentra, Bronchogenic Carcinoma Co-operative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S), Spain; J.J. Crowley, Southwest Oncology Group (SWOG), USA; J.J. Crowley and K.M.W. Pisters, Bimodality Lung Oncology Team (BLOT), USA; T.E. Strand, Cancer Registry of Norway, Norway; S. Swann and H. Choy, Radiation Therapy Oncology Group (RTOG), USA; R. Damhuis, Rotterdam Cancer Registry, The Netherlands; R. Komaki and P. K. Allen, MD Anderson Cancer Center (MDACC-RT), USA; J.P. Sculier and M. Paesmans, European Lung Cancer Working Party (ELCWP); Y.L. Wu, Guangdong Provincial People’s Hospital, Peoples Republic of China; M. Pesek and H. Krosnarova, Faculty Hospital Plzen, Czech Republic; T. Le Chevalier and A. Dunant, International Adjuvant Lung Cancer Trial (IALT), France; B. McCaughan and C. Kennedy, University of Sydney, Sydney, Australia; F. Shepherd and M. Whitehead, National Cancer Institute of Canada (NCIC); J. Jassem and W.Ryzman, Medical University of Gdansk, Poland; G.V. Scagliotti and P. Borasio, Universita’ Degli Studi di Torino, S. Luigi Hospital, Orbassano, Italy; K.M. Fong and L. Passmore, Prince Charles Hospital, Australia; V.W. Rusch and B.J. Park, Memorial Sloan-Kettering Cancer Center, USA; H.J. Baek, Korea Cancer Centre Hospital, Seoul, South Korea; R.P. Perng, Taiwan Lung Cancer Society, Taiwan; R.C. Yung and A. Gramatikova, The Johns Hopkins University, USA; J. Vansteenkiste, Leuven Lung Cancer Group (LLCG), Belgium; C. Brambilla and M. Colonna, Grenoble University Hospital–Isere Cancer Registry, France; J. Hunt and A. Park, Western Hospital, Melbourne, Australia; J.P. Sculier and T. Berghmans, Institute of Jules Bordet, Brussels, Belgium; A.K. Cangir, Ankara University School of Medicine, Ankara, Turkey; D. Subotic, Clinical Centre of Serbia, Belgrade, Serbia; R. Rosell and V. Alberola, Spanish Lung Cancer Group (SLCG), Spain; A.A. Vaporciyan and A.M. Correa, MD Anderson Cancer Center–Thoracic and Cardiovascular Surgery (MDACC-TCVS), USA; J. P. Pignon, T. Le Chevalier, and R. Komaki, Institut Gustave Roussy (IGR), France; T. Orlowski, Institute of Lung Diseases, Warsaw, Poland; D. Ball and J. Matthews, Peter MacCallum Cancer Centre, Melbourne, Australia; M. Tsao, Princess Margaret Hospital, Toronto, Canada; S. Darwish, Policlinic of Perugia, Italy; H.I. Pass and T. Stevens, Karmanos Cancer Institute, Wayne State University, USA; G. Wright, St Vincent’s Hospital, Victoria, Australia; and C. Legrand and J.P. van Meerbeeck, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Cited Here...

Cited By:

This article has been cited 149 time(s).

International Journal of Radiation Oncology Biology Physics
High-Dose Hypofractionated Proton Beam Radiation Therapy Is Safe and Effective for Central and Peripheral Early-Stage Non-Small Cell Lung Cancer: Results of a 12-Year Experience at Loma Linda University Medical Center
Bush, DA; Cheek, G; Zaheer, S; Wallen, J; Mirshahidi, H; Katerelos, A; Grove, R; Slater, JD
International Journal of Radiation Oncology Biology Physics, 86(5): 964-968.
10.1016/j.ijrobp.2013.05.002
CrossRef
Cancer
Survival lmprovements for advanced rage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with lpsilateral lntrapulmonary nodules
Zell, JA; Ou, SHI; Ziogas, A; Anton-Culver, H
Cancer, 112(1): 136-143.
10.1002/cncr.23146
CrossRef
Chest
Staging of lung cancer
Milroy, R
Chest, 133(3): 593-595.
10.1378/chest.07-2638
CrossRef
New England Journal of Medicine
DNA methylation in lung cancer
Park, IK
New England Journal of Medicine, 358(): 2513.

European Respiratory Journal
From surgical to molecular scalpel: ERJ lung cancer series for 2009
Brambilla, C
European Respiratory Journal, 33(1): 9-10.
10.1183/09031936.00162908
CrossRef
Journal of Clinical Oncology
Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
Yee, J; Sadar, MD; Sin, DD; Kuzyk, M; Xing, L; Kondra, J; McWilliams, A; Man, SFP; Lam, S
Journal of Clinical Oncology, 27(): 2787-2792.
10.1200/JCO.2008.19.4233
CrossRef
Archives of Pathology & Laboratory Medicine
Update in Neoplastic Lung Diseases and Mesothelioma
Gordon, IO; Sitterding, S; Mackinnon, AC; Husain, AN
Archives of Pathology & Laboratory Medicine, 133(7): 1106-1115.

Journal of Clinical Oncology
CALGB 9633: An Underpowered Trial With a Methodologically Questionable Conclusion Reply
Strauss, GM; Herndon, JE; Maddaus, MA; Schilsky, RL; Vokes, EE; Green, MR
Journal of Clinical Oncology, 27(): 2301-2302.
10.1200/JCO.2008.21.2126
CrossRef
Targeted Oncology
Targeted therapies in bronchioloalveolar carcinoma
Scagliotti, GV; Selvaggi, G
Targeted Oncology, 3(3): 197-204.
10.1007/s11523-008-0088-3
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Prognostic Significance of Visceral Pleural Invasion and Tumor Size in Non-Small Cell Lung Cancer
Hung, JJ; Liu, JS; Hsu, WH
Journal of Thoracic and Cardiovascular Surgery, 138(1): 260-261.
10.1016/j.jtcvs.2008.12.053
CrossRef
Onkologe
TNM system 2010 Amendments in the new 7th edition of the TNM classification of malignant tumours
Wittekind, C; Bertolini, J
Onkologe, 16(2): 175-180.
10.1007/s00761-009-1776-z
CrossRef
Chest
PET Scan F-18-Fluorodeoxyglucose Uptake and Prognosis in Patients With Resected Clinical Stage IA Non-small Cell Lung Cancer
Nair, VS; Barnett, PG; Ananth, L; Gould, MK
Chest, 137(5): 1150-1156.
10.1378/chest.09-2356
CrossRef
Radiation Oncology
Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study
Hurkmans, CW; Cuijpers, JP; Lagerwaard, FJ; Widder, J; van der Heide, UA; Schuring, D; Senan, S
Radiation Oncology, 4(): -.
ARTN 1
CrossRef
American Journal of Roentgenology
A Radiologic Review of the New TNM Classification for Lung Cancer
Kligerman, S; Abbott, G
American Journal of Roentgenology, 194(3): 562-573.
10.2214/AJR.09.3354
CrossRef
Onkologie
The Boundaries of Curation
Debus, J; Eberhardt, W; Hoffmann, H; Passlick, B; Rube, C; Thomas, M
Onkologie, 33(): 12-20.
10.1159/000313972
CrossRef
Medizinische Klinik
Non-small cell lung cancer - Diagnostics and stage-adapted therapy
Heigener, DF; Reck, M; Gatzemeier, U
Medizinische Klinik, 102(): 981-988.
10.1007/s00063-007-1122-4
CrossRef
Journal of Thoracic Oncology
The International Association for the study of Lung Cancer - Lung Cancer staging project: Proposals regarding the clinical staging of small cell Lung Cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for Lung Cancer
Shepherd, FA; Crowley, J; Van Houtte, P; Postmus, PE; Carney, D; Chansky, K; Shaikh, Z; Goldstraw, P
Journal of Thoracic Oncology, 2(): 1067-1077.

Journal of Thoracic and Cardiovascular Surgery
POINT: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: The problem of understaging
Stiles, BM; Servais, EL; Lee, PC; Port, JL; Paul, S; Altorki, NK
Journal of Thoracic and Cardiovascular Surgery, 137(1): 13-19.
10.1016/j.jtcvs.2008.09.045
CrossRef
Chest
Prognostic significance of the non-size-based AJCC T2 descriptors - Visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size
Ignatius, SH; Zell, JA; Ziogas, A; Anton-Culver, H
Chest, 133(3): 662-669.
10.1378/chest.07-1306
CrossRef
Clinics in Chest Medicine
CT, positron emission tomography, and MRI in staging lung cancer
Erasmus, JJ; Sabloff, BS
Clinics in Chest Medicine, 29(1): 39-+.
10.1016/j.ccm.2007.11.004
CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
Travis, WD; Giroux, DJ; Chansky, K; Crowley, J; Asamura, H; Brambilla, E; Jett, J; Kennedy, C; Rami-Porta, R; Rusch, VW; Goldstraw, P
Journal of Thoracic Oncology, 3(): 1213-1223.

Journal of Clinical Oncology
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Strauss, GM; Herndon, JE; Maddaus, MA; Johnstone, DW; Johnson, EA; Harpole, DH; Gillenwater, HH; Watson, DM; Sugarbaker, DJ; Schilsky, RL; Vokes, EE; Green, MR
Journal of Clinical Oncology, 26(): 5043-5051.
10.1200/JCO.2008.16.4855
CrossRef
Histopathology
Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM Classification based on recommendations of the IASLC Staging Committee
Travis, WD
Histopathology, 54(1): 3-11.
10.1111/j.1365-2559.2008.03179.x
CrossRef
Clinical & Translational Oncology
Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed
Gomez, FM; Palussiere, J; Santos, E; Tourdias, T; Cornelis, F; Saiz, V; Montes, H; Eker, O
Clinical & Translational Oncology, 11(1): 28-34.
10.1007/s12094-009-0307-0
CrossRef
Journal of Thoracic Oncology
Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease
Yang, HX; Hou, X; Lin, P; Yang, H; Zeng, CG; Rong, TH; Fu, JH
Journal of Thoracic Oncology, 4(): 1342-1346.

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
Survival After Surgical Resection of Pulmonary Metastases and Second Primary Squamous Cell Lung Carcinomas in Head and Neck Cancer
Geurts, TW; Balm, AJM; van Velthuysen, MLF; van Tinteren, H; Burgers, JA; van Zandwijk, N; Klomp, HM
Head and Neck-Journal for the Sciences and Specialties of the Head and Neck, 31(2): 220-226.
10.1002/hed.20952
CrossRef
Annals of Thoracic and Cardiovascular Surgery
The Revised TNM Staging System for Lung Cancer
Rami-Porta, R; Crowley, JJ; Goldstraw, P
Annals of Thoracic and Cardiovascular Surgery, 15(1): 4-9.

Archivos De Bronconeumologia
New TNM Classification for Lung Cancer
Porta, RR
Archivos De Bronconeumologia, 45(4): 159-161.
10.1016/j.arbres.2008.09.006
CrossRef
European Journal of Cardio-Thoracic Surgery
The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system
Otiaro, A; Fitosso, PL; Cavallo, A; Giobbe, R; Mossetti, C; Lyberis, P; Cristofori, RC; Ruffini, E
European Journal of Cardio-Thoracic Surgery, 34(2): 438-443.
10.1016/j.ejcts.2008.03.070
CrossRef
Molecular Oncology
Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer
Gerard, C; Debruyne, C
Molecular Oncology, 3(): 409-424.
10.1016/j.molonc.2009.09.001
CrossRef
Annals of Thoracic Surgery
Subcategorization of resectable non-small cell lung cancer involving neighboring structures
Sakakura, N; Mori, S; Ishiguro, F; Fukui, T; Hatooka, S; Shinoda, M; Yokoi, K; Mitsudomi, T
Annals of Thoracic Surgery, 86(4): 1076-1083.
10.1016/j.athoracsur.2008.06.034
CrossRef
Journal of Thoracic Oncology
Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains Proposal for the 7th Edition of the TNM Classification for Lung Cancer
Travis, WD; Brambilla, E; Rami-Porta, R; Vallieres, E; Tsuboi, M; Rusch, V; Goldstraw, P
Journal of Thoracic Oncology, 3(): 1384-1390.

Annals of Thoracic Surgery
N2 Disease in T1 Non-Small Cell Lung Cancer
Defranchi, SA; Cassivi, SD; Nichols, FC; Allen, MS; Shen, R; Deschamps, C; Wigle, DA
Annals of Thoracic Surgery, 88(3): 924-929.
10.1016/j.athoracsur.2009.05.039
CrossRef
Cancer and Metastasis Reviews
Natural history of bronchial preinvasive lesions
Ishizumi, T; McWilliams, A; MacAulay, C; Gazdar, A; Lam, S
Cancer and Metastasis Reviews, 29(1): 5-14.
10.1007/s10555-010-9214-7
CrossRef
Annals of Thoracic Surgery
Prognostic Significance of Intratumoral Blood Vessel Invasion in Pathologic Stage IA Non-Small Cell Lung Cancer
Shoji, F; Haro, A; Yoshida, T; Ito, K; Morodomi, Y; Yano, T; Maehara, Y
Annals of Thoracic Surgery, 89(3): 864-869.
10.1016/j.athoracsur.2009.09.047
CrossRef
European Journal of Cardio-Thoracic Surgery
Staging of ipsilateral pulmonary nodules: back to the future
Van Schil, PE; Hendriks, JM; Lauwers, P
European Journal of Cardio-Thoracic Surgery, 33(3): 484-485.
10.1016/j.ejcts.2007.12.007
CrossRef
Annals of Thoracic Surgery
Survival of Patients With True Pathologic Stage I Non-Small Cell Lung Cancer
Cerfolio, RJ; Bryant, AS
Annals of Thoracic Surgery, 88(3): 917-923.
10.1016/j.athoracsur.2009.05.040
CrossRef
European Journal of Cardio-Thoracic Surgery
Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup
Voltolini, L; Rapicetta, C; Luzzi, L; Ghiribelli, C; Paladini, P; Granato, F; Gallazzi, M; Gotti, G
European Journal of Cardio-Thoracic Surgery, 37(5): 1198-1204.
10.1016/j.ejcts.2009.11.025
CrossRef
Seminars in Radiation Oncology
The Treatment of Early-Stage Disease
Robinson, CG; Bradley, JD
Seminars in Radiation Oncology, 20(3): 178-185.
10.1016/j.semradonc.2010.01.004
CrossRef
Expert Review of Anticancer Therapy
New TNM classification for non-small-cell lung cancer
Tanoue, LT; Detterbeck, FC
Expert Review of Anticancer Therapy, 9(4): 413-423.
10.1586/ERA.09.11
CrossRef
Chest
The Effect of Tumor Size on Non-Size-Based Descriptors in Staging of Stage I Non-small Cell Lung Cancer
Hung, JJ; Liu, JS; Wu, YC; Hsu, WH
Chest, 135(6): 1695.
10.1378/chest.08-2868
CrossRef
Clinical & Translational Oncology
Reflections on the IASLC 12th World Conference on Lung Cancer
Perona, R; Massuti, B; Rosell, R
Clinical & Translational Oncology, 10(2): 67-69.
10.1007/s12094-008-0157-1
CrossRef
Oncology-New York
Proof of efficacy for adjuvant treatment in stage IBNSCLC: Searching for a needle in a haystack?
Ramalingam, SS; Force, S; Khuri, FR
Oncology-New York, 22(5): 522-523.

Chest
Non-sized-based descriptors in staging of stage I non-small cell lung cancer
Lopez-Encuentra, A
Chest, 134(3): 673-674.
10.1378/chest.08-0893
CrossRef
Annals of Thoracic Surgery
Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion
Sakakura, N; Mori, S; Okuda, K; Fukui, T; Hatooka, S; Shinoda, M; Matsuo, K; Yatabe, Y; Yokoi, K; Mitsudomi, T
Annals of Thoracic Surgery, 86(4): 1084-1091.
10.1016/j.athoracsur.2008.04.117
CrossRef
Revista Portuguesa De Pneumologia
The IASLC lung cancer staging project. Comparing the current 6(th) TNM edition with the proposed 7(th) edition
Carvalho, L; Cardoso, E; Nunes, H; Baptista, V; Gornes, A; Couceiro, P
Revista Portuguesa De Pneumologia, 15(1): 67-76.

Journal of Thoracic and Cardiovascular Surgery
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Kameyama, K; Takahashi, M; Ohata, K; Igai, H; Yamashina, A; Matsuoka, T; Nakagawa, T; Okumura, N
Journal of Thoracic and Cardiovascular Surgery, 137(5): 1180-1184.
10.1016/j.jtcvs.2008.09.030
CrossRef
Annals of Thoracic Surgery
Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non-Small Cell Lung Cancer
Demir, A; Turna, A; Kocaturk, C; Gunluoglu, MZ; Aydogmus, U; Urer, N; Bedirhan, MA; Gurses, A; Dincer, SI
Annals of Thoracic Surgery, 87(4): 1014-1022.
10.1016/j.athoracsur.2008.12.053
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population
Kassis, ES; Vaporciyan, AA; Swisher, SG; Correa, AM; Bekele, BN; Erasmus, JJ; Hofstetter, WL; Komaki, R; Mehran, RJ; Moran, CA; Pisters, KM; Rice, DC; Walsh, GL; Roth, JA
Journal of Thoracic and Cardiovascular Surgery, 138(2): 412-U201.
10.1016/j.jtcvs.2009.01.033
CrossRef
Journal of Thoracic Oncology
Against SRT in operable tumors
Van Schil, PE
Journal of Thoracic Oncology, 4(9): S67-S68.

Journal of Clinical Oncology
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer
Blasberg, JD; Pass, HI; Goparaju, CM; Flores, RM; Lee, S; Donington, JS
Journal of Clinical Oncology, 28(6): 936-941.
10.1200/JCO.2009.25.5711
CrossRef
New England Journal of Medicine
Management of Lung Nodules Detected by Volume CT Scanning
Bolukbas, S; Eberlein, M; Schirren, J
New England Journal of Medicine, 362(8): 757-758.

Clinics in Chest Medicine
Radiofrequency Ablation of Lung Tumors
Casal, RF; Tam, AL; Eapen, GA
Clinics in Chest Medicine, 31(1): 151-+.
10.1016/j.ccm.2009.08.021
CrossRef
Future Oncology
Updated lung cancer staging system
Rami-Porta, R; Chansky, K; Goldstraw, P
Future Oncology, 5(): 1545-1553.
10.2217/FON.09.131
CrossRef
Journal of Thoracic and Cardiovascular Surgery
The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: The new era of data-driven revisions
Rusch, VW; Rice, TW; Crowley, J; Blackstone, EH; Rami-Porta, R; Goldstraw, P
Journal of Thoracic and Cardiovascular Surgery, 139(4): 819-821.
10.1016/j.jtcvs.2010.02.013
CrossRef
Journal of Thoracic Oncology
Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer
Lee, JG; Lee, CY; Bae, MK; Park, IK; Kim, DJ; Kim, KD; Chung, KY
Journal of Thoracic Oncology, 3(): 1421-1426.

Journal of Thoracic Oncology
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007
Lim, E; Goldstraw, P; Nicholson, AG; Travis, WD; Jett, JR; Ferolla, P; Bomanji, J; Rusch, VW; Asamura, H; Skogseid, B; Baudin, E; Caplin, M; Kwekkeboom, D; Brambilla, E; Crowley, J
Journal of Thoracic Oncology, 3(): 1194-1201.

Journal of Thoracic and Cardiovascular Surgery
Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers
Fukui, T; Mori, S; Hatooka, S; Shinoda, M; Mitsudomi, T
Journal of Thoracic and Cardiovascular Surgery, 136(5): 1343-1348.
10.1016/j.jtcvs.2007.12.085
CrossRef
Lung Cancer
EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathology
Park, EA; Lee, HJ; Kim, YT; Kang, CH; Kang, KW; Jeon, YK; Goo, JM; Lee, CH; Park, CM
Lung Cancer, 64(2): 179-186.
10.1016/j.lungcan.2008.08.003
CrossRef
Annals of Thoracic Surgery
Survival and Risk Factors of Surgically Treated Mediastinal Invasion T4 Non-Small Cell Lung Cancer
Yang, HX; Hou, X; Lin, P; Rong, TH; Yang, H; Fu, JH
Annals of Thoracic Surgery, 88(2): 372-379.
10.1016/j.athoracsur.2009.04.018
CrossRef
Chest
The Case of a Good Satellite Outcomes of Resected Ipsilateral Same-Lobe Satellite Pulmonary Nodules
Molina, JR
Chest, 136(3): 660-662.
10.1378/chest.09-0897
CrossRef
European Journal of Cardio-Thoracic Surgery
Recommended changes for Tand N descriptors proposed by the International Association for the Study of Lung Cancer - Lung Cancer Staging Project: a validation study from a single-centre experience
Ruffini, E; Filosso, PL; Bruna, MC; Coni, F; Cristofori, RC; Mossetti, C; Solidoro, P; Oliaro, A
European Journal of Cardio-Thoracic Surgery, 36(6): 1037-1044.
10.1016/j.ejcts.2009.05.051
CrossRef
Seminars in Respiratory and Critical Care Medicine
Staging of non-small cell lung cancer
Tanoue, LT
Seminars in Respiratory and Critical Care Medicine, 29(3): 248-260.
10.1055/s-2008-1076745
CrossRef
Oncology-New York
Adjuvant treatment of stage IBNSCLC - The problem of stage subset heterogeneity " - The David Rice article reviewed"
Calhoun, R; Jablons, D; Lau, D; Gandara, DR
Oncology-New York, 22(5): 511-516.

Chest
Non-sized-based descriptors in staging of stage I non-small cell lung cancer - Response
Ou, SHI; Zell, JA
Chest, 134(3): 674.
10.1378/chest.08-1475
CrossRef
Journal of Thoracic Oncology
Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival
Skov, BG; Krasnik, M; Lantuejoul, S; Skov, T; Brambilla, E
Journal of Thoracic Oncology, 3(): 1410-1415.

Archives of Pathology & Laboratory Medicine
Protocol for the Examination of Specimens From Patients With Primary Non-Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung
Butnor, KJ; Beasley, MB; Cagle, PT; Grunberg, SM; Kong, FM; Marchevsky, A; Okby, NT; Roggli, VL; Suster, S; Tazelaar, HD; Travis, WD
Archives of Pathology & Laboratory Medicine, 133(): 1552-1559.

Human Pathology
Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling
Yousem, SA
Human Pathology, 40(6): 861-867.
10.1016/j.humpath.2008.11.008
CrossRef
Chest
The New Lung Cancer Staging System
Detterbeck, FC; Boffa, DJ; Tanoue, LT
Chest, 136(1): 260-271.
10.1378/chest.08-0978
CrossRef
Cancer Radiotherapie
Stereotactic radiotherapy for stage I lung cancer: Current results and new developments
Senan, S; Lagerwaard, F
Cancer Radiotherapie, 14(2): 115-118.
10.1016/j.canrad.2009.11.003
CrossRef
Journal of Thoracic and Cardiovascular Surgery
The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer
Aokage, K; Yoshida, J; Ishii, G; Enatsu, S; Hishida, T; Nishimura, M; Nishiwaki, Y; Nagai, K
Journal of Thoracic and Cardiovascular Surgery, 139(5): 1246-U181.
10.1016/j.jtcvs.2009.07.049
CrossRef
Journal of Thoracic Oncology
How new staging affects surgical perspectives
Rami-Porta, R
Journal of Thoracic Oncology, 4(9): S150-S152.

Oncologist
Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer
Bordoni, R
Oncologist, 13(9): 945-953.
10.1634/theoncologist.2008-0062
CrossRef
Journal of the Korean Medical Association
Staging of Lung Cancer
Kim, HY
Journal of the Korean Medical Association, 51(): 1118-1124.

Journal of Thoracic Oncology
Implementation of IASLC revised staging system: imaging implications
Patz, EF
Journal of Thoracic Oncology, 4(9): S16-S17.

Journal of Thoracic Oncology
Positron Emission Tomography F-18-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic Review
Nair, VS; Krupitskaya, Y; Gould, MK
Journal of Thoracic Oncology, 4(): 1473-1479.

Annals of Thoracic Surgery
Molecular biologic staging of lung cancer
D'Amico, TA
Annals of Thoracic Surgery, 85(2): S737-S742.
10.1016/j.athoracsur.2007.11.047
CrossRef
Oncologist
Critical review of nonsurgical treatment options for stage I non-small cell lung cancer
Haasbeek, CJA; Senan, S; Smit, EF; Paul, MA; Slotman, BJ; Lagerwaard, FJ
Oncologist, 13(3): 309-319.
10.1634/theoncologist.2007-0195
CrossRef
European Journal of Cardio-Thoracic Surgery
Survival after resection of synchronous bilateral lung cancer
De Leyn, P; Moons, J; Vansteenkiste, J; Verbeken, E; Van Raemdonck, D; Nafteux, P; Decaluwe, H; Lerut, T
European Journal of Cardio-Thoracic Surgery, 34(6): 1215-1222.
10.1016/j.ejcts.2008.07.069
CrossRef
Journal of Thoracic Oncology
Validation of the proposed International Association for the study of Lung Cancer non-small cell Lung Cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry
Zell, JA; Ou, SHI; Ziogas, A; Anton-Culver, H
Journal of Thoracic Oncology, 2(): 1078-1085.

Expert Review of Anticancer Therapy
Surgery for oligometastatic disease in non-small-cell lung cancer
Van Schil, PE; Hendriks, JM; Carp, L; Lauwers, PR
Expert Review of Anticancer Therapy, 8(): 1931-1938.
10.1586/14737140.8.12.1931
CrossRef
Lung Cancer
Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer
Shim, HS; Park, IK; Lee, CY; Chung, KY
Lung Cancer, 65(2): 161-165.
10.1016/j.lungcan.2008.11.008
CrossRef
Journal of Thoracic Oncology
Clinical implications of the new staging system: pulmonary and oncology perspective
Dubey, S
Journal of Thoracic Oncology, 4(9): S275-S276.

Population Health Management
An Actuarial Approach to Comparing Early Stage and Late Stage Lung Cancer Mortality and Survival
Goldberg, SW; Mulshine, JL; Hagstrom, D; Pyenson, BS
Population Health Management, 13(1): 33-46.
10.1089/pop.2009.0010
CrossRef
Journal of Thoracic Oncology
Implementation of IASLC revised staging system: taking the new staging system into the clinic
Rusch, VW
Journal of Thoracic Oncology, 4(9): S17-S18.

Journal of Thoracic Oncology
Update in Staging of Lung Cancer
Erasmus, JJ
Journal of Thoracic Oncology, 4(9): S69-S71.

Chest
Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data
William, WN; Lin, HY; Lee, JJ; Lippman, SM; Roth, JA; Kim, ES
Chest, 136(3): 701-709.
10.1378/chest.08-2968
CrossRef
Chest
Subdivision of the T1 Size Descriptor for Stage I Non-small Cell Lung Cancer Has Prognostic Value A Single Institution Experience
Ye, C; Masterman, JR; Huberman, MS; Gangadharan, SP; McDonald, DC; Kent, MS; DeCamp, MM
Chest, 136(3): 710-715.
10.1378/chest.09-0823
CrossRef
Chest
Details and Difficulties Regarding the New Lung Cancer Staging System
Detterbeck, FC; Boffa, DJ; Tanoue, LT; Wilson, LD
Chest, 137(5): 1172-1180.
10.1378/chest.09-2626
CrossRef
Asian Pacific Journal of Cancer Prevention
Involvement of FoxM1 in Non-Small Cell Lung Cancer Recurrence
Xu, N; Wu, SD; Wang, H; Wang, Q; Bai, CX
Asian Pacific Journal of Cancer Prevention, 13(9): 4739-4743.
10.7314/APJCP.2012.13.9.4739
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer
Hamaji, M; Allen, MS; Cassivi, SD; Deschamps, C; Nichols, FC; Wigle, DA; Shen, R
Journal of Thoracic and Cardiovascular Surgery, 145(3): 683-691.
10.1016/j.jtcvs.2012.12.051
CrossRef
Oncotargets and Therapy
New dilemmas in small-cell lung cancer TNM clinical staging
Zarogoulidis, K; Latsios, D; Porpodis, K; Zarogoulidis, P; Darwiche, K; Antoniou, N; Hohenforst-Schmidt, W; Eleftheriadou, E; Boutsikou, E; Kontakiotis, T
Oncotargets and Therapy, 6(): 539-547.
10.2147/OTT.S44201
CrossRef
Diagnostic and Interventional Radiology
Measurements of tumor size using CT and PET compared to histopathological size in non-small cell lung cancer
Aydin, F; Dertsiz, L; Budak, ES; Yildiz, A; Ozbilim, G; Gungor, F
Diagnostic and Interventional Radiology, 19(4): 271-278.
10.5152/dir.2013.053
CrossRef
Annals of Oncology
Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma
Tsutani, Y; Miyata, Y; Nakayama, H; Okumura, S; Adachi, S; Yoshimura, M; Okada, M
Annals of Oncology, 24(9): 2376-2381.
10.1093/annonc/mdt230
CrossRef
Korean Journal of Radiology
Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival
Lee, Y; Lee, HJ; Kim, YT; Kang, CH; Goo, JM; Park, CM; Paeng, JC; Chung, DH; Jeon, YK
Korean Journal of Radiology, 14(2): 375-383.
10.3348/kjr.2013.14.2.375
CrossRef
Acta Oncologica
Validation of the 7th TNM classification for non-small cell lung cancer: A retrospective analysis on prognostic implications for operated node-negative cases
Bergman, P; Brodin, D; Lewensohn, R; de Petris, L
Acta Oncologica, 52(6): 1189-1194.
10.3109/0284186X.2012.742960
CrossRef
Plos One
Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis
Ulivi, P; Mercatali, L; Casoni, GL; Scarpi, E; Bucchi, L; Silvestrini, R; Sanna, S; Monteverde, M; Amadori, D; Poletti, V; Zoli, W
Plos One, 8(2): -.
ARTN e57401
CrossRef
Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery
Relationship of T-stage and nodal metastases according to the up-to-date clinical TNM staging in lung cancer
Candas, F
Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery, 21(1): 258.
10.5606/tgkdc.dergisi.2013.7207
CrossRef
Journal of Cardiothoracic Surgery
Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
Park, SY; Lee, JG; Kim, J; Byun, GE; Bae, MK; Lee, CY; Kim, DJ; Chung, KY
Journal of Cardiothoracic Surgery, 8(): -.
ARTN 151
CrossRef
Lung Cancer
Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies
Locher, C; Debieuvre, D; Coetmeur, D; Goupil, F; Molinier, O; Collon, T; Dayen, C; Le Treut, J; Asselain, B; Martini, F; Blanchon, F; Grivaux, M
Lung Cancer, 81(1): 32-38.
10.1016/j.lungcan.2013.03.001
CrossRef
Annals of Surgical Oncology
Predictive Factors of Lymph Node Status in Small Peripheral Non-small Cell Lung Cancers: Tumor Histology is More Reliable
Zhang, Y; Sun, YH; Shen, L; Li, Y; Xiang, JQ; Zhang, YW; Hu, H; Chen, HQ
Annals of Surgical Oncology, 20(6): 1949-1954.
10.1245/s10434-012-2829-x
CrossRef
Chest
Point: Are Limited Resections Appropriate in Non-small Cell Lung Cancer? Yes
Donington, JS
Chest, 141(3): 588-590.
10.1378/chest.11-3108
CrossRef
Current Oncology
Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer
Zuccato, JA; Ellis, PM
Current Oncology, 19(6): E422-E427.
10.3747/co.19.1133
CrossRef
Annals of Thoracic Surgery
Routine Intraoperative Frozen Section Analysis of Bronchial Margins Is of Limited Utility in Lung Cancer Resection
Owen, RM; Force, SD; Gal, AA; Feingold, PL; Pickens, A; Miller, DL; Fernandez, FG
Annals of Thoracic Surgery, 95(6): 1859-1866.
10.1016/j.athoracsur.2012.12.016
CrossRef
Annals of Thoracic Surgery
Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
David, E; Thall, PF; Kalhor, N; Hofstetter, WL; Rice, DC; Roth, JA; Swisher, SG; Walsh, GL; Vaporciyan, AA; Wei, C; Mehran, RJ
Annals of Thoracic Surgery, 95(6): 1872-1877.
10.1016/j.athoracsur.2013.03.085
CrossRef
Neoplasia
The Proangiogenic Phenotype of Natural Killer Cells in Patients with Non-Small Cell Lung Cancer
Bruno, A; Focaccetti, C; Pagani, A; Imperatori, AS; Spagnoletti, M; Rotolo, N; Cantelmo, AR; Franzi, F; Capella, C; Ferlazzo, G; Mortara, L; Albini, A; Noonan, DM
Neoplasia, 15(2): 133-U191.
10.1593/neo.121758
CrossRef
Surgery Today
Surgical treatment for non-small cell lung cancer with ipsilateral pulmonary metastases
Okamoto, T; Iwata, T; Mizobuchi, T; Hoshino, H; Moriya, Y; Yoshida, S; Yoshino, I
Surgery Today, 43(): 1123-1128.
10.1007/s00595-012-0452-x
CrossRef
Journal of Clinical Oncology
New Staging System: How Does It Affect Our Practice?
Goldstraw, P
Journal of Clinical Oncology, 31(8): 984-991.
10.1200/JCO.2012.42.7922
CrossRef
Radiotherapy and Oncology
The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05)
Ball, DL; Fisher, RJ; Burmeister, BH; Poulsen, MG; Graham, PH; Penniment, MG; Vinod, SK; Krawitz, HE; Joseph, DJ; Wheeler, GC; McClure, BE
Radiotherapy and Oncology, 106(3): 305-311.
10.1016/j.radonc.2012.12.003
CrossRef
European Journal of Cardio-Thoracic Surgery
Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)
Fibla, JJ; Cassivi, SD; Decker, PA; Allen, MS; Darling, GE; Landreneau, RJ; McKenna, RJ; Putnam, JB
European Journal of Cardio-Thoracic Surgery, 43(5): 911-914.
10.1093/ejcts/ezs520
CrossRef
European Respiratory Journal
Survival of lung adenocarcinoma patients with malignant pleural effusion
Wu, SG; Yu, CJ; Tsar, MF; Liao, WY; Yang, CH; Jan, IS; Yang, PC; Shin, JY
European Respiratory Journal, 41(6): 1409-1418.
10.1183/09031936.00069812
CrossRef
Interactive Cardiovascular and Thoracic Surgery
Transoesophageal endoscopic ultrasound-guided fine-needle aspiration of pleural effusion for the staging of non-small cell lung cancer
Lococo, F; Cesario, A; Attili, F; Chiappetta, M; Leuzzi, G; Costamagna, G; Granone, P; Larghi, A
Interactive Cardiovascular and Thoracic Surgery, 17(2): 237-241.
10.1093/icvts/ivt166
CrossRef
Lung Cancer
Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set
Fibla, JJ; Cassivi, SD; Brunelli, A; Decker, PA; Allen, MS; Darling, GE; Landreneau, RJ; Putnam, JB
Lung Cancer, 78(3): 259-262.
10.1016/j.lungcan.2012.09.010
CrossRef
Journal of Thoracic Disease
Photodynamic therapy for the treatment of non-small cell lung cancer
Simone, CB; Friedberg, JS; Glatstein, E; Stevenson, JP; Sterman, DH; Hahn, SM; Cengel, KA
Journal of Thoracic Disease, 4(1): 63-75.
10.3978/j.issn.2072-1439.2011.11.05
CrossRef
Medical Oncology
Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer
Zhang, J; Huang, SH; Li, H; Li, Y; Chen, XL; Zhang, WQ; Chen, HG; Gu, LJ
Medical Oncology, 30(1): -.
ARTN 352
CrossRef
Current Opinion in Pulmonary Medicine
Principles of staging as applied to nonsmall cell lung cancer
Filner, JJ; Ost, D
Current Opinion in Pulmonary Medicine, 14(4): 287-291.
10.1097/MCP.0b013e328302406f
PDF (89) | CrossRef
The Cancer Journal
Use of the Proposals of the International Association for the Study of Lung Cancer in the Forthcoming Edition of Lung Cancer Staging System to Predict Long-Term Prognosis of Operated Patients
Rena, O; Massera, F; Robustellini, M; Papalia, E; Delfanti, R; Lisi, E; Pirondini, E; Turello, D; Casadio, C
The Cancer Journal, 16(2): 176-181.
10.1097/PPO.0b013e3181ce474e
PDF (419) | CrossRef
Journal of Thoracic Oncology
Verification of the Newly Proposed T Category (Seventh Edition of the Tumor, Node, and Metastasis Classification) from a Clinicopathological Viewpoint in Non-small Cell Lung Cancer—Special Reference to Tumor Size
Yano, T; Morodomi, Y; Ito, K; Yoshida, T; Haro, A; Shoji, F; Koga, T; Maehara, Y
Journal of Thoracic Oncology, 5(1): 45-48.
10.1097/JTO.0b013e3181c0996c
PDF (389) | CrossRef
Journal of Thoracic Oncology
Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry
Ou, SI; Zell, JA
Journal of Thoracic Oncology, 3(3): 216-227.
10.1097/JTO.0b013e318164545d
PDF (1150) | CrossRef
Journal of Thoracic Oncology
The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition
Ignatius Ou, S; Zell, JA
Journal of Thoracic Oncology, 4(3): 300-310.
10.1097/JTO.0b013e318194a355
PDF (2516) | CrossRef
Journal of Thoracic Oncology
Anatomy, Biology and Concepts, Pertaining to Lung Cancer Stage Classification
Detterbeck, FC; Tanoue, LT; Boffa, DJ
Journal of Thoracic Oncology, 4(4): 437-443.
10.1097/JTO.0b013e31819852ed
PDF (423) | CrossRef
Journal of Thoracic Oncology
Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients
Nakao, M; Yoshida, J; Ishii, G; Hishida, T; Nishimura, M; Nagai, K
Journal of Thoracic Oncology, 5(4): 504-509.
10.1097/JTO.0b013e3181ccb391
PDF (1058) | CrossRef
Journal of Thoracic Oncology
Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC
Kawaguchi, T; Takada, M; Kubo, A; Matsumura, A; Fukai, S; Tamura, A; Saito, R; Maruyama, Y; Kawahara, M; Ignatius Ou, S
Journal of Thoracic Oncology, 5(5): 620-630.
10.1097/JTO.0b013e3181d2dcd9
PDF (1722) | CrossRef
Journal of Thoracic Oncology
The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer
Chansky, K; Sculier, J; Crowley, JJ; Giroux, D; Van Meerbeeck, J; Goldstraw, P; on behalf of the International Staging Committee and Participating Institutions,
Journal of Thoracic Oncology, 4(7): 792-801.
10.1097/JTO.0b013e3181a7716e
PDF (632) | CrossRef
Journal of Thoracic Oncology
Analysis of Survival in 400 Surgically Resected Non-small Cell Lung Carcinomas: Towards a Redefinition of the T Factor
Lyons, G; Quadrelli, S; Silva, C; Vera, K; Iotti, A; Venditti, J; Chertcoff, J; Chimondeguy, D
Journal of Thoracic Oncology, 3(9): 989-993.
10.1097/JTO.0b013e3181838b19
PDF (325) | CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
Vallières, E; Shepherd, FA; Crowley, J; Van Houtte, P; Postmus, PE; Carney, D; Chansky, K; Shaikh, Z; Goldstraw, P; on Behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions,
Journal of Thoracic Oncology, 4(9): 1049-1059.
10.1097/JTO.0b013e3181b27799
PDF (624) | CrossRef
Advances in Anatomic Pathology
An Update on Lung Cancer Staging
Jones, KD
Advances in Anatomic Pathology, 17(1): 33-37.
10.1097/PAP.0b013e3181c66f15
PDF (318) | CrossRef
Annals of Surgery
Limited Resection for the Treatment of Patients With Stage IA Lung Cancer
Wisnivesky, JP; Henschke, CI; Swanson, S; Yankelevitz, DF; Zulueta, J; Marcus, S; Halm, EA
Annals of Surgery, 251(3): 550-554.
10.1097/SLA.0b013e3181c0e5f3
PDF (205) | CrossRef
Journal of Thoracic Oncology
Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer
Okubo, K; Bando, T; Miyahara, R; Sakai, H; Shoji, T; Sonobe, M; Fujinaga, T; Sato, K; Wada, H; Tanaka, T
Journal of Thoracic Oncology, 4(2): 203-207.
10.1097/JTO.0b013e3181949c6a
PDF (312) | CrossRef
Journal of Thoracic Oncology
Synchronous, Separate, and Similar
Detterbeck, FC
Journal of Thoracic Oncology, 5(2): 150-152.
10.1097/JTO.0b013e3181c81500
PDF (139) | CrossRef
Journal of Thoracic Oncology
Outcome of Surgical Resection for Pathologic N0 and Nx Non-small Cell Lung Cancer
Osarogiagbon, RU; Allen, JW; Farooq, A; Berry, A; Spencer, D; O'Brien, T
Journal of Thoracic Oncology, 5(2): 191-196.
10.1097/JTO.0b013e3181c8cc32
PDF (459) | CrossRef
Journal of Thoracic Oncology
Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers
Finley, DJ; Yoshizawa, A; Travis, W; Zhou, Q; Seshan, VE; Bains, MS; Flores, RM; Rizk, N; Rusch, VW; Park, BJ
Journal of Thoracic Oncology, 5(2): 197-205.
10.1097/JTO.0b013e3181c814c5
PDF (1263) | CrossRef
Journal of Thoracic Oncology
State of the Journal
Jett, JR
Journal of Thoracic Oncology, 3(3): 203-204.
10.1097/JTO.0b013e318166624a
PDF (31) | CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project: Revision Proposal of Pleural Effusion and Controlateral Nodule Staging
Barbieri, V; Tassone, P; Tagliaferri, P
Journal of Thoracic Oncology, 3(3): 317.
10.1097/JTO.0b013e318166b84a
PDF (95) | CrossRef
Journal of Thoracic Oncology
IASLC Lung Cancer Staging Project—A Radiologist Perspective
Raj, JV; Coulden, R; Entwisle, J
Journal of Thoracic Oncology, 3(3): 318-319.
10.1097/JTO.0b013e318165c183
PDF (95) | CrossRef
Journal of Thoracic Oncology
The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition
Sculier, J; Chansky, K; Crowley, JJ; Van Meerbeeck, J; Goldstraw, P; on behalf of the International Staging Committee and Participating Institutions,
Journal of Thoracic Oncology, 3(5): 457-466.
10.1097/JTO.0b013e31816de2b8
PDF (621) | CrossRef
Journal of Thoracic Oncology
CD24, a Novel Cancer Biomarker, Predicting Disease-Free Survival of Non-small Cell Lung Carcinomas: A Retrospective Study of Prognostic Factor Analysis from the Viewpoint of Forthcoming (Seventh) New TNM Classification
Lee, H; Choe, G; Jheon, S; Sung, S; Lee, C; Chung, J
Journal of Thoracic Oncology, 5(5): 649-657.
10.1097/JTO.0b013e3181d5e554
PDF (1362) | CrossRef
Journal of Thoracic Oncology
The 7th Edition of TNM in Lung Cancer: What Now?
Goldstraw, P
Journal of Thoracic Oncology, 4(6): 671-673.
10.1097/JTO.0b013e31819e7814
PDF (163) | CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project
Giroux, DJ; Rami-Porta, R; Chansky, K; Crowley, JJ; Groome, PA; Postmus, PE; Rusch, V; Sculier, J; Shepherd, FA; Sobin, L; Goldstraw, P; On behalf of the International Association for the Study of Lung Cancer International Staging Committee,
Journal of Thoracic Oncology, 4(6): 679-683.
10.1097/JTO.0b013e3181a52370
PDF (268) | CrossRef
Journal of Thoracic Oncology
Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China
Li, Z; Yu, Y; Lu, J; Luo, Q; Wu, C; Liao, M; Zheng, Y; Ai, X; Gu, L; Lu, S
Journal of Thoracic Oncology, 4(6): 702-709.
10.1097/JTO.0b013e3181a5269d
PDF (686) | CrossRef
Journal of Thoracic Oncology
Lumping, Splitting, and Sorting
Detterbeck, FC
Journal of Thoracic Oncology, 2(7): 581-582.
10.1097/JTO.0b013e31807a2fae
PDF (29) | CrossRef
Journal of Thoracic Oncology
Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion
Niho, S; Kubota, K; Yoh, K; Goto, K; Ohmatsu, H; Nihei, K; Saijo, N; Nishiwaki, Y
Journal of Thoracic Oncology, 3(7): 723-727.
10.1097/JTO.0b013e31817c606a
PDF (213) | CrossRef
Journal of Thoracic Oncology
Survival Prognostication in Non-small Cell Lung Cancer
Zell, JA; Ignatius Ou, S
Journal of Thoracic Oncology, 4(7): 785-786.
10.1097/JTO.0b013e3181a99fa2
PDF (119) | CrossRef
Journal of Thoracic Oncology
Staging Metastasis Profile of Non-small Cell Lung Cancer: A New Paradigm?
Pujol, JL; Chakra, M
Journal of Thoracic Oncology, 2(8): 679-681.
10.1097/JTO.0b013e31812d05f4
PDF (38) | CrossRef
Journal of Thoracic Oncology
A Seismic Shift in Staging
Silvestri, GA
Journal of Thoracic Oncology, 2(8): 682-683.
10.1097/JTO.0b013e318145af89
PDF (33) | CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer
Postmus, PE; Brambilla, E; Chansky, K; Crowley, J; Goldstraw, P; Patz, EF; Yokomise, H; on behalf of the International Association for the Study of Lung Cancer International Staging Committee,a Cancer Research and Biostatistics,b Observer,
Journal of Thoracic Oncology, 2(8): 686-693.
10.1097/JTO.0b013e31811f4703
PDF (508) | CrossRef
Journal of Thoracic Oncology
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P; Crowley, J; Chansky, K; Giroux, DJ; Groome, PA; Rami-Porta, R; Postmus, PE; Rusch, V; Sobin, L; on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions,
Journal of Thoracic Oncology, 2(8): 706-714.
10.1097/JTO.0b013e31812f3c1a
PDF (596) | CrossRef
Journal of Thoracic Oncology
We Probably have the Answer: Now What is the Question?
Goldstraw, P; Rami-Porta, R; Crowley, J
Journal of Thoracic Oncology, 4(8): 939-940.
10.1097/JTO.0b013e3181a76e42
PDF (117) | CrossRef
Nuclear Medicine Communications
Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion
Duysinx, B; Corhay, J; Larock, M; Nguyen, D; Bury, T; Hustinx, R; Louis, R
Nuclear Medicine Communications, 29(11): 982-986.
10.1097/MNM.0b013e32830978c4
PDF (96) | CrossRef
Back to Top | Article Outline
Keywords:

IASLC International Staging Committee; TNM classification of lung cancer; Lung cancer staging; Tumor size; Malignant pleural effusion; Complete resection

© 2007International Association for the Study of Lung Cancer

Login

Article Tools

Images

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.